Results 71 to 80 of about 165,276 (249)

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith   +23 more
wiley   +1 more source

Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection

open access: yesScientific Reports
Rituximab occasionally induces reactivation of hepatitis C virus (HCV) in patients with resolved HCV infection, sometimes with fatal consequences. As rituximab has become one of the first-line therapies for the treatment of phospholipase A2 receptor ...
Xiaodan Li   +7 more
doaj   +1 more source

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multi‐Omic Analysis: Insights into Cardiovascular and Renal Complications

open access: yesArthritis &Rheumatology, Accepted Article.
Background Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó   +84 more
wiley   +1 more source

Targeting panoptosis: a narrative review of its therapeutic potential in kidney disease

open access: yesBMC Nephrology
Renal diseases are major global public health challenges due to their complex mechanisms and growing burden. PANoptosis, a unified programmed cell death pathway driven by the PANoptosome complex, involves the combined activation of pyroptotic, apoptotic,
Yuxin Guo   +8 more
doaj   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng   +14 more
wiley   +1 more source

Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated
Alexandre O. Gérard   +11 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Circ-0069561 as a novel diagnostic biomarker for progression of diabetic kidney disease

open access: yesRenal Failure
Background Circular RNAs (circRNAs) are non-coding RNAs that are key regulators of the initiation and progression of various human diseases. However, the role of circRNAs in diabetic kidney disease (DKD) remains unknown.Methods Whole high-throughput RNA ...
Chaoyi Chen   +7 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Dupilumab‐Related Adverse Events and Intolerance in Aspirin‐Exacerbated Respiratory Disease Patients

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Lancelot P. Herpin   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy